Premier Perspectives The blog for insider insights in clinical development Medical and Regulatory Affairs ANDA or 505(b)(2): Choosing the Right Abbreviated Approval Pathway for Your Drug By Rahul Chandrasekhar June 29, 2021 × ALSO OF INTERESTKey Considerations When Designing a Phase 1...7 Questions About Clinical Evaluations for MDRNostalgia or Shell Shock? Assessing PTSD Is a...